Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 21

1.

CD4+ T cell-mediated HLA class II cross-restriction in HIV controllers.

Galperin M, Farenc C, Mukhopadhyay M, Jayasinghe D, Decroos A, Benati D, Tan LL, Ciacchi L, Reid HH, Rossjohn J, Chakrabarti LA, Gras S.

Sci Immunol. 2018 Jun 8;3(24). pii: eaat0687. doi: 10.1126/sciimmunol.aat0687.

PMID:
29884618
2.

A T Cell Receptor Locus Harbors a Malaria-Specific Immune Response Gene.

Van Braeckel-Budimir N, Gras S, Ladell K, Josephs TM, Pewe L, Urban SL, Miners KL, Farenc C, Price DA, Rossjohn J, Harty JT.

Immunity. 2017 Nov 21;47(5):835-847.e4. doi: 10.1016/j.immuni.2017.10.013. Epub 2017 Nov 14.

PMID:
29150238
3.

A conserved energetic footprint underpins recognition of human leukocyte antigen-E by two distinct αβ T cell receptors.

Sullivan LC, Walpole NG, Farenc C, Pietra G, Sum MJW, Clements CS, Lee EJ, Beddoe T, Falco M, Mingari MC, Moretta L, Gras S, Rossjohn J, Brooks AG.

J Biol Chem. 2017 Dec 22;292(51):21149-21158. doi: 10.1074/jbc.M117.807719. Epub 2017 Sep 25.

PMID:
28972140
4.

Germline bias dictates cross-serotype reactivity in a common dengue-virus-specific CD8+ T cell response.

Culshaw A, Ladell K, Gras S, McLaren JE, Miners KL, Farenc C, van den Heuvel H, Gostick E, Dejnirattisai W, Wangteeraprasert A, Duangchinda T, Chotiyarnwong P, Limpitikul W, Vasanawathana S, Malasit P, Dong T, Rossjohn J, Mongkolsapaya J, Price DA, Screaton GR.

Nat Immunol. 2017 Nov;18(11):1228-1237. doi: 10.1038/ni.3850. Epub 2017 Sep 25.

5.

Reversed T Cell Receptor Docking on a Major Histocompatibility Class I Complex Limits Involvement in the Immune Response.

Gras S, Chadderton J, Del Campo CM, Farenc C, Wiede F, Josephs TM, Sng XYX, Mirams M, Watson KA, Tiganis T, Quinn KM, Rossjohn J, La Gruta NL.

Immunity. 2016 Oct 18;45(4):749-760. doi: 10.1016/j.immuni.2016.09.007. Epub 2016 Oct 4.

6.

The targeted recognition of Lactococcus lactis phages to their polysaccharide receptors.

McCabe O, Spinelli S, Farenc C, Labbé M, Tremblay D, Blangy S, Oscarson S, Moineau S, Cambillau C.

Mol Microbiol. 2015 May;96(4):875-86. doi: 10.1111/mmi.12978. Epub 2015 Mar 16.

7.

Molecular insights on the recognition of a Lactococcus lactis cell wall pellicle by the phage 1358 receptor binding protein.

Farenc C, Spinelli S, Vinogradov E, Tremblay D, Blangy S, Sadovskaya I, Moineau S, Cambillau C.

J Virol. 2014 Jun;88(12):7005-15. doi: 10.1128/JVI.00739-14. Epub 2014 Apr 9.

8.

A toxin-antitoxin module of Salmonella promotes virulence in mice.

De la Cruz MA, Zhao W, Farenc C, Gimenez G, Raoult D, Cambillau C, Gorvel JP, Méresse S.

PLoS Pathog. 2013;9(12):e1003827. doi: 10.1371/journal.ppat.1003827. Epub 2013 Dec 19.

9.

Structure, adsorption to host, and infection mechanism of virulent lactococcal phage p2.

Bebeacua C, Tremblay D, Farenc C, Chapot-Chartier MP, Sadovskaya I, van Heel M, Veesler D, Moineau S, Cambillau C.

J Virol. 2013 Nov;87(22):12302-12. doi: 10.1128/JVI.02033-13. Epub 2013 Sep 11.

10.

Viral infection modulation and neutralization by camelid nanobodies.

Desmyter A, Farenc C, Mahony J, Spinelli S, Bebeacua C, Blangy S, Veesler D, van Sinderen D, Cambillau C.

Proc Natl Acad Sci U S A. 2013 Apr 9;110(15):E1371-9. doi: 10.1073/pnas.1301336110. Epub 2013 Mar 25.

11.

Fragment based lead discovery of small molecule inhibitors for the EPHA4 receptor tyrosine kinase.

van Linden OP, Farenc C, Zoutman WH, Hameetman L, Wijtmans M, Leurs R, Tensen CP, Siegal G, de Esch IJ.

Eur J Med Chem. 2012 Jan;47(1):493-500. doi: 10.1016/j.ejmech.2011.11.020. Epub 2011 Nov 18.

PMID:
22137457
12.

Clopidogrel pharmacodynamics and pharmacokinetics in the fed and fasted state: a randomized crossover study of healthy men.

Hurbin F, Boulenc X, Daskalakis N, Farenc C, Taylor T, Bonneau D, Lacreta F, Cheng S, Sultan E.

J Clin Pharmacol. 2012 Oct;52(10):1506-15. Epub 2011 Nov 29.

PMID:
22128201
13.

Crystal structure of the EphA4 protein tyrosine kinase domain in the apo- and dasatinib-bound state.

Farenc C, Celie PH, Tensen CP, de Esch IJ, Siegal G.

FEBS Lett. 2011 Nov 16;585(22):3593-9. doi: 10.1016/j.febslet.2011.10.028. Epub 2011 Oct 22.

14.

Genetic polymorphisms and the impact of a higher clopidogrel dose regimen on active metabolite exposure and antiplatelet response in healthy subjects.

Simon T, Bhatt DL, Bergougnan L, Farenc C, Pearson K, Perrin L, Vicaut E, Lacreta F, Hurbin F, Dubar M.

Clin Pharmacol Ther. 2011 Aug;90(2):287-95. doi: 10.1038/clpt.2011.127. Epub 2011 Jun 29.

PMID:
21716274
15.
16.

Prodrugs of bisthiazolium salts are orally potent antimalarials.

Vial HJ, Wein S, Farenc C, Kocken C, Nicolas O, Ancelin ML, Bressolle F, Thomas A, Calas M.

Proc Natl Acad Sci U S A. 2004 Oct 26;101(43):15458-63. Epub 2004 Oct 18.

17.

Pharmacodynamics and atracurium and laudanosine concentrations during a fixed continuous infusion of atracurium in mechanically ventilated patients with acute respiratory distress syndrome.

Lefrant JY, Farenc C, De la Coussaye JE, Muller L, Ripart J, Cuvillon P, Saissi G, Eledjam JJ.

Anaesth Intensive Care. 2002 Aug;30(4):422-7.

18.

Quantitative determination of rocuronium in human plasma by liquid chromatography-electrospray ionization mass spectrometry.

Farenc C, Enjalbal C, Sanchez P, Bressolle F, Audran M, Martinez J, Aubagnac JL.

J Chromatogr A. 2001 Feb 23;910(1):61-7.

PMID:
11263576
19.

Pharmacokinetic-pharmacodynamic modeling of atracurium in intensive care patients.

Farenc C, Lefrant JY, Audran M, Bressolle F.

J Clin Pharmacol. 2001 Jan;41(1):44-50.

PMID:
11144993
20.

Pk-fit: a pharmacokinetic/pharmacodynamic and statistical data analysis software.

Farenc C, Fabreguette JR, Bressolle F.

Comput Biomed Res. 2000 Oct;33(5):315-29.

PMID:
11017724
21.

High-performance liquid chromatographic method for the determination of atracurium and laudanosine in human plasma. Application to pharmacokinetics.

Farenc C, Audran M, Lefrant JY, Mazerm I, Bressolle F.

J Chromatogr B Biomed Sci Appl. 1999 Mar 5;724(1):117-26.

PMID:
10202964

Supplemental Content

Loading ...
Support Center